Development Safety Update Report (DSUR)
Definition
The Development Safety Update Report (DSUR) is an annual report submitted to regulatory authorities that summarizes the safety information of a drug under clinical development. It is a key component of pharmacovigilance, ensuring that any potential risks associated with a drug are identified and managed effectively during its development phase.
Detailed Explanation
Purpose and Importance of DSUR
The DSUR serves as a comprehensive safety summary for a drug in development, providing regulators with a detailed analysis of all available safety data. Its primary aim is to ensure patient safety by identifying new risks, confirming known risks, and assessing the need for changes in the drug’s development plan.
Contexts of Use
The DSUR is used by pharmaceutical companies and regulatory bodies to:
- Monitor the safety profile of investigational drugs.
- Make informed decisions regarding the continuation, modification, or termination of clinical trials.
- Align with international safety reporting standards, particularly in multi-regional clinical trials.
Applications in Pharmacovigilance
In pharmacovigilance, the DSUR is an essential tool for maintaining a proactive approach to drug safety. It involves the collection, analysis, and interpretation of data from various sources, including clinical trials, literature, and patient reports.
Examples of what a DSUR might include:
- A summary of significant safety findings from clinical trials during the reporting period.
- An evaluation of the drug’s safety profile in light of new information.
- Updates on the status of ongoing and completed clinical trials.
- Information on the drug’s benefit-risk balance.
Related Topics
Related documents and concepts include:
- Investigator’s Brochure (IB)
- Periodic Safety Update Report (PSUR)
- Risk Management Plan (RMP)
References
For more detailed information, please refer to the following regulatory guidance:
